Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.

‘Population autopsy’ finds the US with more avoidable deaths than other wealthy countries
The United States appears to be leading all high-income countries in an unfortunate, distinctly undesirable statistical category.
Bayer's new imaging agent for cardiac amyloidosis impresses in clinical trial
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
AATS helps heart surgeons diagnose and manage heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia after heart surgery is a major concern, but prior guidelines were developed without much feedback from actual cardiac surgeons.
FDA announces more recalls due to risk of syringe breaking during treatment
Medline already had to recall millions of syringes due to a significant safety risk. Now, multiple procedure kits that include the devices are also being recalled. The issue has been associated with four serious injuries.
How expert guidelines have influenced TAVR vs. SAVR decisions
As popular as TAVR is today, SAVR continues to play a significant role in the management of patients with valvular disease.

Society of Thoracic Surgeons launches new risk calculators for SAVR after TAVR, other key heart surgeries

STS risk calculators are known as a go-to resource for cardiologists, surgeons and any other healthcare providers who manage the care of heart patients.

Confirmed: AFib ablation more beneficial for patients with HFrEF than those with HFpEF

Researchers explored data from nearly 2,500 AFib ablation patients, sharing their findings in JAMA Cardiology.

An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.

Cardiologists share update after world’s first implant of new optimizer device for tricuspid regurgitation

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.

Could diamond dust replace gadolinium in MRI contrast agents?

An accidental discovery could have future implications for the material makeup for MRI contrast media.

Cardiology groups share key update: ABMS seeking feedback on proposed Board of Cardiovascular Medicine

Five of the largest U.S. medical societies focused on cardiovascular health are one step closer to seeing their paradigm-shifting proposal become a reality.

FDA clears new catheter for peripheral blood clots

The new-look catheter came out of a medical device incubator started by entrepreneur Eitan Konstantino, PhD, who has years of experience in the vascular space.

noncompete contract clause employment pen sign

Cardiologists, thoracic surgeons applaud FTC’s ban of most noncompete clauses

The Society for Cardiovascular Angiography & Interventions and Society of Thoracic Surgeons have both shared statements in support of the ban, which is already being challenged in court. The American Hospital Association, meanwhile, opposes the policy shift, saying it “errs by seeking to create a one-size-fits-all rule”

Statin therapy may help HFpEF patients lower their risk of death, heart attack or stroke

All participants were free of ASCVD and had no history of statin use at the start of the study.

Clinical

‘Population autopsy’ finds the US with more avoidable deaths than other wealthy countries

Bayer's new imaging agent for cardiac amyloidosis impresses in clinical trial

AATS helps heart surgeons diagnose and manage heparin-induced thrombocytopenia

FDA announces more recalls due to risk of syringe breaking during treatment

How expert guidelines have influenced TAVR vs. SAVR decisions